Head-to-head evidence
Diroximel fumarate vs DRF
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Sclerosis
Shared mechanism: Nrf2 pathway (fumaric acid ester) · full Multiple Sclerosis pipeline
Diroximel fumarate · Vumerity
Marketed by Biogen
NCT05083923 · Phase 3 · completed
The study was a single-group, open-label trial with 136 participants enrolled and no placebo or active comparator. Its primary outcomes were safety measures rather than a comparative clinical efficacy endpoint, so there was no formal primary treatment comparison to meet or miss; the reported safety findings are descriptive only.
Next expected readout: July 2034 · NCT07483632 (registry estimate)
DRF
Marketed by Biogen
NCT05083923 · Phase 3 · completed
The study was single-arm and open-label, with no randomization, blinding, or control group; 102 participants received treatment. Its posted primary outcomes were safety measures rather than a controlled clinical efficacy comparison, so there was no formal primary endpoint comparison to meet or miss.
Next expected readout: July 2034 · NCT07483632 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Diroximel fumarate's landscape · DRF's landscape